Germany backed away from a plan to implement variable discount pricing on branded drugs, Reuters reporting that opposition from drugmakers drove the change. The proposed discount initiative was part of a healthcare reform plan intended to reduce drug spending, with projected savings tied to a larger markdown structure on list prices paid to insurers. Instead of moving forward with variable discounts, Germany reportedly opted for a fixed plan while leaving details to be finalized. Drugmakers had warned that the reform would push them to cut investments in the country, including Eli Lilly and Boehringer Ingelheim. The shift signals continued volatility in European pricing frameworks—an issue that affects market entry strategy and expected returns for biotech portfolios.